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ABSTRACT 
 
The role of Src-homology 2 domain-containing tyrosine phosphatase 
2 in signaling and tumorigenesis of basal type/triple negative breast 
cancer 
 
 Fatimah Matalkah  
Basal type/triple negative breast cancer (BTBC) represents a distinct tumor group that is 
characterized by an aggressive disease phenotype and poor clinical outcome.  Patients with this 
subtype cannot benefit from the available anti-hormone and anti-HER2 targeted therapies (e.g. 
tamoxifen and herceptin).  Therefore, characterizing potential therapeutic targets is urgently 
needed.  We reasoned that the Src-homology 2 domain-containing tyrosine phosphatase 2 
(SHP2) could serve as a therapeutic target in BTBC, because of its critical regulation of 
epidermal growth factor recptor (EGFR) which is overexpressed in BTBC.  Here, we 
demonstrated that SHP2 knockdown in BTBC cell lines suppressed cell proliferation, migration, 
and transformation.  Furthermore, inhibition of SHP2 decreased the level of MMP9 in the 
conditioned media as shown by zymography and affected the invasive phenotype of BTBC cell 
lines in 3D matrigel.  Most importantly, the results obtained from xenografts confirm that SHP2 
plays an important role in the maintenance and progression of BTBC development and lung 
metastasis.  Mechanistically, SHP2 depletion resulted in less-sustained EGF-induced Ras 
activation and decreased β-catenin level, the latter of which resulted in an increase in p27 level.  
Taken together, these observations suggest that SHP2 plays essential roles in the development of 
BTBC and provide a rationale for targeting SHP2 in BTBC.  
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1.1 The disease of cancer 
Cancer is a complex multigenic disease, encompassing more than 100 entities arising from 
different types of cells and organs of the human body [1].  Each tumor type has unique somatic 
and epigenetic alterations [2].  The major known somatic alterations are mutations, chromosomal 
re-arrangement, copy number gains or losses, and integration of nucleic acid of foreign origin 
(e.g viral genome) [3].  On the other hand, the epigenetic alterations include changes in DNA 
methylation, histone modification, and non-coding RNA mediating silencing of protein 
expression [4].  It is just this complexity that is believed to hamper the development of a 
universally effective therapy for all different types of cancer.  
The causes of cancer are many and varied including genetic and environmental factors, as 
well as infectious agents [1].  Moreover, around 30% of cancer deaths in the world are related to 
lifestyle and personal behaviors, which include tobacco smoking, alcohol consumption, and diets 
low in fruits and vegetables. Collectively, these factors can transform a normal cell into a 
malignant cell by driving specific series of genetic and epigenetic changes in proto-oncogenes, 
tumor suppressor genes, and other genes that control normal cell function [5].  Mutations 
affecting proto-oncogenes are typically activating in nature providing the transformed cell with 
new properties.  These include sustained cell growth and proliferation, protection from 
programmed cell death, and the ability to adapt to different tissue microenvironments.  However, 
mutations affecting tumor suppressor genes in cancer cells are loss of function mutations.  
Generally, the loss of function in tumor suppressor genes results in loss of accurate DNA 
replication, inability to control cell cycle, and loss of cell polarity [6].  Overall, these mutations 
affecting tumor suppressor genes and proto-oncogenes result in tumor development and 
metastasis.  In general, a cell that has acquired a cancerous state exhibits the following 
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properties: self-sufficiency in growth signals, insensitivity to growth inhibitory signals, evasion 
of apoptosis signals, sustaining proliferation and angiogenesis, tissue invasion, and metastasis 
[6].  
Cancer is a major public health problem around the world resulting in 13% of all human 
death.  According to the World Health Organization, 7.6 million people died from cancer during 
2008.  In the United States cancer is responsible for about 25% of all deaths, making it the 
second leading cause of death after heart disease. In 2012 nearly one and a half million are 
expected to be diagnosed with cancer, and about half a million Americans will die of cancer [7].  
As of 2011, the most prevalent type of cancer amongst males in the United States is prostate 
cancer, whereas in females it is breast cancer.  However, the leading cause of death in both males 
and females is lung cancer, which contributes approximately 30% of all deaths due to cancer [8].  
Cancer treatment costs billions of dollars, causing a financial burden for victims of cancer 
and society as a whole.  In  2007 the National Institute of Health estimated the cost of cancer at 
226.8 billion dollars due to both medical expenses and lost productivity [8].  Moreover, 
according to the World Health Organization, death from cancer worldwide is expected to keep 
rising with an estimated 13.1 million deaths in 2030.   
In conclusion, cancer represents a huge burden to the economy and to public health 
worldwide.  Ongoing research is needed to decrease suffering and death due to cancer.  
Identifying the genetic and protein changes in cancer cells would provide prognostic markers and 
molecular targets for therapeutic intervention [9].  
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1.2 Breast Cancer  
1.2.1 Epidemiology and pathophysiology of breast cancer 
Breast cancer is a type of cancer that affects the breast tissues.  And like any other type of 
cancer the exact causes are unknown, but both environmental and genetic factors are involved.  
Breast cancer can strike both males and females; however, women are much more likely to 
develop the disease than men [10].  Worldwide, breast cancer is the second leading cause of 
cancer-related death in women, with almost 1.4 million diagnoses and approximately 500,000 
deaths in 2008 [11].  In the United States, breast cancer is the most common form of cancer 
among women after skin cancer, with over 200,000 diagnoses and nearly 40,000 deaths in 2011, 
ranking as the second leading cause of cancer-related deaths in women after lung cancer [7].   
Breast cancer is a malignant tumor that grows in one or both of the breasts, and usually 
develops in the ducts and the lobules, the milk-producing area of the breast.  There are different 
types of breast cancer that can be grouped based on their tissue penetrance into two main 
categories-noninvasive and invasive.  The non-invasive type can be further divided into two 
types: ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS). As their name 
suggests, DCIS and LCIS are confined to the ducts and lobules of the breast, respectively, and 
they don’t invade the surrounding tissue.  The invasive breast tumors can also be divided into 
two types:  infiltrating ductal carcinoma and infiltrating lobular carcinoma.  Invasive carcinoma 
types are more serious than the noninvasive tumor types, and as their name suggest these tumors 
invade the wall of the ducts and lobules, respectively, and infiltrate outside of it, spreading to 
different parts of the body such as the lung, bone, liver and brain.  The most common type of 
breast cancer is infiltrating ductal carcinoma, accounting for 70-80% of all the cases.  More 
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often, mortality from breast cancer is due to metastasis, in which tumor cells spread to distant 
sites and form secondary tumors that interfere with the function of vital organs.  
Treatment options that are available for patients with breast cancer include surgery, 
radiotherapy, chemotherapy, and anti-hormonal/anti-HER2 targeted therapies.  There are two 
surgical options available for patients with breast cancer; lumpectomy, where only the tumor 
tissue is removed, and mastectomy in which the whole breast is removed.  The surgical option is 
often accompanied by other treatment options such as radiotherapy or chemotherapy.  On the 
other hand, the anti-hormonal and anti-HER2 targeted therapies are only applicable to patients 
with the hormonal receptors-positive (ER/PR+) and epidermal growth factor 2 (HER2)-
overexpressing tumors, respectively.  Diagnosis with hormone-positive tumors is considered 
good prognosis for patients since these tumors are less aggressive and respond well to targeted 
therapies (e.g., Tamoxifen).  Although targeted therapy is available to HER2-overexpressing 
tumors, these tumors are characterized with aggressive growth and development of resistance.  
Furthermore, the emergence of therapy-resistant cancer cells is one of the unavoidable 
consequences of targeted therapy [12].  As a result, significant numbers of patients do not show a 
response to treatment or experience relapse and disease progression from which they will 
succumb [10].   
Despite significant improvements in breast cancer treatment strategies, current therapies are 
limited by the emergence of therapy-resistant cancer cells and the disease remains the most 
deadly cancer in women worldwide [12].  Understanding the underlying resistance mechanisms 
and identifying new therapeutic targets has been one of the most intense areas of breast cancer 
research [10, 13]. 
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1.2.2 Breast cancer classification 
Breast cancer is a heterogeneous disease in terms of histology, gene expression, and response 
to therapy. Two taxonomy systems have been proposed and used in an attempt to clarify such 
heterogeneity. The clinical system, which relies on immunohistochemistry to identify the 
presence of several receptors, namely estrogen (ER), progesterone (PR), and epidermal growth 
factor 2 (HER2) classifies breast cancer into three subtypes [14, 15].  These are ER/PR positive, 
HER2-overexpressing, and triple negative tumors. The more recent system, pioneered by Perou 
and colleagues, allows the subtypes to be assessed based on gene expression by the microarray 
technique [14, 16-19].  Such classification defines five distinct subtypes of breast cancer. These 
include luminal A, luminal B, HER2-overexpressing, basal-like, and normal breast-like [16, 17].  
A recently-added subtype is the claudin low that is believed to be enriched for cells with stem-
like markers, which have an elevated ability to proliferate and form new tumors [18].  The 
luminal (A and B) are ER-positive groups that express genes normally found in the luminal cells 
lining the inner layer of breast ducts, therefore, they are termed the “luminal group” [14].  On the 
other hand, HER2-overexpressing tumors are characterized by overexpression of HER2 receptor 
and the genes associated with the HER2 pathway.  The normal breast-like subtype is poorly 
characterized with the notion that this subtype is an artifact of the expression profiling. 
Therefore, the clinical significance of this subtype is yet to be determined.  Of particular concern 
is the basal-like subtype, which accounts for up to 10-20 % of all breast cancer cases, but is 
responsible for a disproportionately higher number of deaths [14, 15, 18, 19].  The major factors 
are the highly metastatic nature of the disease and the absence of targeted therapy. 
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1.2.3 Basal-like breast cancer subtype 
Basal–like tumors represent 10-20 % of all breast carcinomas, and are so named because they 
express genes normally found in basal/myoepithelial cells of the breast including high molecular 
weigh cytokeratins CK5 and CK17.  Clinically, they affect younger patients, are more prevalent 
in African-American women and are associated with unfavorable outcome.  Histologically, the 
basal-like tumors are characterized by high histological grade, and high mitotic indices [15].  
They commonly lack expression of estrogen receptor, progesterone receptor as well as HER2 
receptor; a feature referred to as triple negative [15, 19].  The triple negative phenotype itself 
defines an aggressive disease that lack the benefit of targeted therapy available for the other 
subtypes, specifically the hormonal therapy targeting the ER/PR-expressing tumors, and 
trastuzumab targeting the HER2-overexpersssing breast tumors.  Interestingly, there exists more 
than 85% overlap between the basal-like and triple negative tumors in gene expression profile 
[20].  This overlap has led to the interchangeable use of these terms by many investigators and to 
the acceptance of triple negative as a surrogate for basal-like [15, 19].  Therefore, this study 
focused on the basal-like tumors that are triple negative; hence the term basal-like and triple-
negative breast cancer has been used throughout the text (BTBC). 
 BTBC tumors express genes that are associated with myoepithelial cells such as cytokeratins 
(CK 5/6, CK 14, CK17), P-cadherin, and smooth muscle markers (α-smooth muscle actin) [20].  
Most of BTBC are positive for epidermal growth factor receptor (EGFR) and protein tyrosine 
kinase Kit (c- Kit) [14].    Currently, BTBC is the most challenging subtype of breast cancer as 
there are no targeted therapies available.  As such, chemotherapy is the only form of systematic 
treatment available for patients with this subtype.  Although some patients respond very well to 
chemotherapy initially they eventually develop resistance leading to disease recurrence and 
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fatality [15].  There are several potential targeted therapies that have been identified and are 
currently in preclinical and clinical trials.  Some of the drug targets being explored are the 
receptor tyrosine kinases that include EGFR, c-Kit, hepatocyte growth factor receptor (HGFR), 
and Insulin-like growth factor I receptor (IGF-IR), and the cytoplasmic protein kinase c-Src.  In 
addition, efforts are underway to target protein  kinases that are involved in the signaling 
transduction pathway of the mitogen activated protein kinase (MAPK), and the 
phosphatidylinositol-3-kinase/ Serine threonine kinase Akt (PI3K/Akt) pathways [12, 14, 15, 
21].  Unfortunately, preliminary results from the clinical trials indicate it is unlikely that a single 
agent will serve the purpose of effectively treating all patients.  It is most likely that a 
combination therapy of targeted and general cytotoxic agents will be the most effective way in 
treating patients with this subtype [15].  
Despite the ongoing efforts, no effective targeted therapy has been developed yet.  Therefore, 
research on new targets is warranted.  This study has focused on the Src homology 2 (SH2) 
containing phosphatase 2 (SHP2) which is a well-known regulator of receptor tyrosine kinase-
induced signaling, especially that of epidermal growth factor receptor (EGFR) [22].   
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1.3 The Structure of SHP2 (PTPN11) and activation 
The Src homology 2 (SH2) containing phosphatase 2 (SHP2) is a cytoplasmic protein 
tyrosine phosphatase (PTP), encoded by the PTPN11 gene in humans, and is ubiquitously 
expressed in various tissue and cell types.  It belongs to a highly conserved subfamily of 
cytoplasmic tyrosine phosphatase that includes itself and its structural homologus SHP1 [23-25].  
The invertebrate homologus of SHP2 include corkscrew in Drosophila and Ptp-2 in C. elegans 
[25].  Structurally, SHP2 consists of two tandem-arranged SH2 domains at the amino-terminus 
(N-SH2 and C-SH2 respectively), a single tyrosine phosphatase domain (PTP) carboxyl-terminal 
to the SH2 domains, and a C-terminal tail that contains two tyrosine residues and a proline- rich 
motif with unknown function [24, 26, 27].  The SH2 domains have two important functions.  1) 
They are required for recruitment of SHP2 to the micro-domain of its substrates; 2) and they 
regulate the enzyme activity particularly accomplished by the N-SH2 [23, 25, 26].  
The crystal structure of SHP2 revealed that SHP2 is auto-inhibited by intramolecular 
interactions between the N-SH2 and PTP domains under basal condition, blocking substrate 
access and the enzyme activity [27, 28].  Binding of a phosphorylated tyrosine (pY) to the SH2 
domains induces conformational changes in the N-SH2 domain, exposing the PTP domain, and 
activating the enzyme as shown in (Fig.1).  
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Figure (1): Schematic of SHP2 activation: In the absence of growth factor stimulation SHP2 is 
maintained in a closed confirmation (inactive) by intramolecular interaction between the N-SH2 
domain and the PTP domain.  Binding of a competing peptide with double p-Tyr-residues to the 
N-SH2 and C-SH2 domains causes SHP2 to assume open confirmation with subsequent 
activation of the PTP domain. 
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1.4 SHP2 (PTPN11) in cell signaling 
SHP2 has emerged as one of the rare PTPs that in many cases positively enhances signal 
transduction rather than inhibiting [27].  Several biochemical and genetic studies indicate that 
SHP2 is widely involved in transducing signals from various growth factors, cytokines, 
hormones, and extracellular matrices (ECM) [23, 25, 27, 29, 30]. Therefore, SHP2 has been 
implicated to function in the coordination and integration of several biological processes such as 
cell growth, survival, migration, differentiation and cell death [23, 29].  A great body of evidence 
demonstrates that SHP2 is a positive regulator (signal-enhancing) of the Ras/MAPK pathway 
downstream of RTKs and cytokine receptors [23, 24].  As such, SHP2 is required for full and 
sustained activation of the Ras/MAPK pathway [27, 30].  For example, in fibroblast cells that 
express a mutant SHP2 lacking the N-terminal SH2 domain, which is believed to be a loss of 
function mutation (SHP2−/−), the MAPK activation in response to epidermal growth factor 
(EGF), insulin like growth factor (IGF), platelet derive growth factor (PDGF), and fibroblast 
growth factor (FGF) was lower or at least unsustained compared to wild type expressing cell 
[27].  Furthermore, microinjection of catalytically inactive mutant of SHP2 mRNA in Xenopus 
embryos blocked FGF-induced stimulation of extracellular-signal regulated kianse (ERK) 
activation [31, 32].  Also, overexpression of catalyically inactive SHP2 mutant in 3T3 cells 
blocked insulin-induced activation of mitogen activated protein kinase (MAPK) [33]. 
Different mechanisms have been suggested for SHP2 regulation of the Ras/MAPK pathway.  
First, SHP2 can dephosphorylate the binding sites for the GTPase-activating protein RasGAP on 
RTKs (e.g. EGFR and PDGFR) and scaffolding molecules such as Gab protein and receptor 
substrates (e.g. insulin and fibroblast receptor substrates) [25, 30, 34].  Second, SHP2 promotes 
activation of the Ras/MAPK pathway by dephosphorylating Sprouty, a known negative regulator 
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of this signaling pathway.  Dephosphorylation of Sprouty by SHP2 negatively regulates its 
activity and enhances the signaling through the Ras/ MAPK pathway [27, 30].  Furthermore, 
SHP2 has been suggested to activate the Ras/MAPK pathway by regulating Src activity either 
through direct dephosphorylation or by inhibiting the recruitment of the Src negative regulator 
Csk [25, 30].  There is definitely no shortage in the suggested mechanisms as to how SHP2 
activates the Ras/MAPK pathway; however, one should keep in mind that receptor and/or cell 
type dependence could be the reason for the emergence of several candidates [30].  
SHP2 has also been suggested to regulate the (PI3K/Akt) and RhoA pathways.  Receptor 
type or cell context determines whether SHP2 acts positively or negatively [35, 36].  For 
example, it has been shown that SHP2 associates with the P85 subunit of PI3K, leading to its 
activation upon stimulation with IGF-1 and PDGF in glioblastoma and fibroblast cells [35, 36].  
However, others have shown that SHP2 acts as a negative regulator of the EGF-induced PI3K 
activation in fibroblasts that express the mutant form of SHP2 (SHP2−/−) [35, 36].  For instance, 
upon EGF stimulation of the (SHP2−/−) fibroblasts there is an increased association between 
P85 subunit and Gab1, suggesting a mechanism where SHP2 negatively regulates the PI3K 
pathway by dephosphorylating a P85 binding sites on Gab1 [36].  
SHP2 has also been implicated in the regulation of Janus kinase/ signal transducers and 
activators of transcription (JAK/STAT) and the nuclear transcription factor (NF-κB) downstream 
of cytokine receptors.  Previous studies demonstrated that SHP2 positively regulates the NF-κB 
activation induced by IL-1 and tumor necrosis factor (TNF), which leads to IL-6 secretion.  In 
contrast to its role in NF-κB activation, SHP2 plays a negative role in the induction of the 
JAK/STAT pathway induced by interferon [37].  In doing so, SHP2 appears to function as a pro-
survival factor protecting the cell from the cytotoxic effect of interferon.  In general, the 
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combined effect of SHP2 on both NF-κB and interferon-stimulated JAK/STAT pathway could 
provide a mechanism into how SHP2 exerts its protective effect against cell death [38]. 
Recently, SHP2 has been implicated in Wnt signaling gene expression.  The suggested SHP2 
substrate that mediates the effect in Wnt signaling is parafibromin/Cdc73, a component of the 
nuclear RNA polymerase II-associated factor (PAF) [39].  Dephosphorylation by SHP2 converts 
parafibromin from being a trans-suppressor of c-myc and cyclin-D1expression into an activator 
of Wnt signaling gene expression [39].  Furthermore, SHP2 has been implicated in the increased 
β-catenin nuclear localization via inhibition of its interaction with α-catenin [40].   
In summary, SHP2 appears to function in various signaling pathways that include 
Ras/MAPK, PI3K, JAK/STAT, NF-κB, and Wnt signaling.  These observations imply a 
combined signaling function for SHP2 in that it may act at multiple signaling sites at the same 
time to coordinate and integrate multiple cellular processes such as, cell growth, survival, 
motility, and cell death [29]. 
 
1.5 SHP2 in transformation and cancer 
SHP2 is the first human phosphatase that was found to act as a proto-oncogene.  Somatic 
PTPN11 mutations that disturb the auto-inhibited state and activate the enzyme have been linked 
to different types of leukemia [41].  For example, D61Y and E76K are the most common 
activating mutations in SHP2 occurring in sporadic juvenile myelomonocytic leukemia (JMML) 
and accounting for approximately 35% of the cases [42, 43].  These SHP2 mutations affect the 
N-SH2 domain residues that are involved in the auto-inhibited state causing the enzyme to 
assume an active state.  SHP2 activating mutations are also found in other myeloid neoplasms 
but in lower incidences.  These include 5-10% of childhood myelodysplastic syndrome (MDS), 
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7% of B cell-acute lymphocytic leukemia B-ALL, some cases of acute mylogenous leukemia 
(AML), and chronic myelomonocytic leukemia (CMML) [28, 41, 42, 44].  
PTPN11 somatic mutations are rare in solid tumors; nevertheless, PTPN11 activating 
mutations have been detected in a very low prevalence in breast cancer, neuroblastoma, lung 
adenocarcinoma, melanoma, and colorectal cancer [44].  While mutations affecting SHP2 in 
solid tumors are infrequent and very rare, wild type SHP2 is an essential component positively 
enhancing the signaling pathways downstream of growth factor receptors and proto-oncogenes 
that have significant contributions in cancer [42].   
  SHP2 has also been implicated in the severe gastritis and gastric carcinoma caused by the 
bacterium Helicobacter pylori that have the cytotoxin associated Antigen A (CagA) gene [42, 
45].  The CagA protein, once delivered into the infected gastric epithelial cells, undergoes 
tyrosine phosphorylation by Src family kinases (SFK) on EPIYA motifs, which provides a high 
affinity binding site for SHP2 [45]. Therefore, tyrosine phosphorylated CagA recruits and 
activates SHP2. Once SHP2 is activated, it acts to transmit positive signals that promote cell 
growth and motility. In fact, several studies demonstrate that the virulence factor CagA, acting 
through SHP2, is the critical mechanism by which CagA promotes gastric carcinoma [28, 45]. 
For example, knocking down SHP2 diminishes the CagA-induced hummingbird phenotype, 
which is characterized by enhanced spreading and elongation in gastric epithelial cells [45].   
Similarly, aberrant expression of normal scaffolding proteins like Gab2 can contribute to 
oncogenesis by activating wild type SHP2.  Indeed, Gab2 is frequently overexpressed in breast 
cancer, and several experimental studies showed that Gab2, acting through SHP2, can promote 
excessive proliferation of mammary epithelial cells and can mediate transformation and 
tumorigenesis induced by HER2 [42, 46].  
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Most importantly, previous work has demonstrated that SHP2 expression is upregulated in 
infiltrating ductal carcinoma (IDC) [47]. SHP2 was overexpressed in approximately 79% and 
67% of HER2-positive and HER-negative IDC tumors, respectively, with strong association to 
higher tumor grade and lymph node metastasis [47].  Moreover, SHP2 has been shown to 
promote breast cancer cell transformation, and its inhibition leads to mesenchymal to epithelial 
transition (MET), the opposite of EMT (epithelial to mesenchymal transition) [48]. 
Very recently, an important function for SHP2 in promoting mammary tumorigenesis in vivo 
has been established.  It has been shown that inhibition of SHP2 by shRNA in breast cancer cells 
suppresses tumor growth in animal xenograft models [49]. 
To sum up, while SHP2 mutations are infrequent in solid tumors, strong evidence has 
implicated the wild type SHP2 activation either by overexpression or by other mechanisms (e.g. 
activation by protein tyrosine kinases) in transformation and tumor growth of cancer cells. 
 
1.6 Hypothesis and objectives 
Earlier work has shown that SHP2 is overexpressed in approximately 75% of IDC of the 
breast with strong association to higher tumor grade and lymph node metastasis [50].  
Furthermore, it has been shown that SHP2 is required for maintaining the transformed phenotype 
and for sustaining the EMT process in breast cancer cell lines that overexpress EGFR or HER2 
[48, 50].  Altogether, these data imply a significant role for SHP2 in breast cancer.  
BTBC presents the most challenging subtype of breast cancer to treat.  Therefore, identifying 
and characterizing new therapeutic targets is urgently needed.  Based on the previous evidence 
implying a role for shp2 in breast cancer oncogenesis, we hypothesize that SHP2 is important for 
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the transformation and tumorigenic potential of breast cancer cell lines typical to BTBC tumors.  
Therefore, this study was aimed at investigating the following specific objectives:  
 
I. Produce stably infected breast cancer cell lines that constitutively express anti-
SHP2 shRNA from BTBC cell lines (e.g. MDA-MB-231 and MDA-MB-468). 
 
II. Investigate if SHP2 inhibition impacts cell proliferation, transformation, and 
invasion in cell culture conditions. 
 
III. Determine if inhibition of SHP2 abolishes the tumorigenic and metastatic 
potential of the BTBC cells in NOD/SCID mice. 
 
IV. Study the signaling pathways affected by SHP2 depletion 
 
1.7 Significant contributions 
In this study we have shown that SHP2 promotes the transformation and tumorigenic 
potential of BTBC cells under cell culture and in vivo condition.  We also provide evidence 
showing a positive role for SHP2 in the metastatic potential of BTBC cells.  The results show 
that tumor growth of basal type breast cancer cell lines MDA-MB-468 and MDA-MB-231 
depends on SHP2.  Depletion of SHP2 protein suppressed anchorage-independence growth, cell 
proliferation, wound healing, and the invasive phenotype of BTBC cells.  Mechanistically, SHP2 
depletion decreased β-catenin levels, increased p27 expression, and was necessary for EGF-
induced sustained Ras activation.  We also show that SHP2 is required for the self-renewal 
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capacity of the tumor initiating cells (TICs) in BTBC cells.  Collectively, our results provide new 
insights into the signaling networks promoting tumor progression and metastasis in BTBC as 
well as a rationale for considering SHP2 as a potential therapeutic target in BTBC.  
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2. MATERIALS AND METHODS 
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2.1 Reagents and cell culture 
The breast cancer cell lines MDA-MB-468 and MDA-MB-231 were purchased from ATCC.  
Cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal 
bovine serum, non-essential amino acids, and an antimycotic/antibiotic solution (Mediatech, 
Inc.).  Cells were maintained at 37ºC in 5% CO2 humidified atmosphere.  Primary antibodies 
used in this study included anti-β-catenin with 1:1000 dilution (catalog # sc-7963), anti-pan 
ERK2 with 1:1000 dilution (catalog # sc-154), and anti-P27 with 1:1000 dilution (catalog # sc-
528) purchased from Santa Cruz.  The anti-β-actin with 1:3000 dilution (catalog # A5441) was 
purchased from Sigma and anti-PTP1D with 1:1000 dilution (SHP2) (catalog # sc-7384) was 
from Pharmagen. Anti- pan AKT with 1:1000 dilution (catalog # 06-558) and anti-GST with 
1:2000 dilution (catalog # 05-311) were from Upstate Technology.   Anti- MMP9 with 1:1000 
dilution (catalog # AB13458) was from Millipore, while anti-Ras with 1:1000 dilution (catalog # 
610002) was obtained from Transduction Laboratories.  Secondary antibodies used included 
sheep anti-mouse and goat anti-rabbit conjugated to horseradish peroxidase purchased from 
Amersham.  Matrigel was purchased from BD Bioscience (Bedford, MA), and the EdU Alexa 
Flour 647 was from Molecular Probes (Invitrogen, OR). 
 
2.2 Preparation of cell and tissue lysates  
Cell lysates were collected by washing cells twice with cold 1X phosphate buffered saline 
(PBS) followed by incubation on ice for 20 minutes with 500 µl of cell lysis buffer (20 mM Tris-
HCl, pH 7.4, 150 mM NaCl, 50 mM NaF, 1 mM EDTA, 10% glycerol, 1% Triton X-100, 1 mM 
sodium orthovanadate, 1 mM PMSF, 1 µg/ml aprotinin, 1 µg/ml leupeptin).  Cells were scraped 
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to bring cells into suspension.  To collect lysates from tumor samples, tissues were dissected, and 
then quickly mixed with cell lysis buffer, minced into small pieces on ice.  Samples were 
sonicated at low setting (power setting to 2) and then incubated on ice for 30 minutes.  Lysates 
were cleared by centrifugation at 13,000 rpm for 20 minutes at 4ºC. Supernatant was then used 
for analysis. 
 
2.3 Polyacrylamide gel electrophoresis (PAGE) and immunoblotting analysis 
Equal amounts of lysates were resolved with 8% or 10% denaturing polyacrylamide gel 
(SDS-PAGE).  Separated proteins were transferred to nitrocellulose membranes (Thermo 
scientific, IL), blocked with 3% bovine serum albumin (BSA) in Tris-Buffered Saline Tween 20 
(TBST) at room temperature for 1 hour, and then incubated with a primary antibody in TBST 
either overnight at 4ºC or for 2 hours at room temperature.  After washing 3 times with TBST 
buffer (25 mM Tris.HCl, pH 7.4, 150 mM NaCl, 0.1% Tween 20) the membranes were 
incubated with a secondary antibody in 5% milk for 1 hour at room temperature.  
Chemiluminescence detection was used to visualize proteins (Perkin Elmer). 
 
2.4 Short hairpin ribonucleic acid (shRNA) construction and stable cell line production 
Short double-stranded oligonucleotides for SHP2 protein inhibitionwere custom-synthesized 
(Integrated DNA Technology) and were ligated into the BamHI and EcoRI site of the lentivirus 
pLSL-Puro (a gift from Dr. Peter Chumskoy, Cleveland Clinic Foundation). The targeting 
sequences 5’-GTATTACATGGAACATCAC-3’  and 5’-GAAGAATCCTATGGTGGAA-3’ as 
previously described [51].  Briefly, after ligation overnight at 16 ºC, XL-blue bacteria were 
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transformed with the ligated vector. Transformed bacteria with Ampicillin resistance were grown 
on agar plate and used to inoculate a small volume culture of Luria broth (LB) containing 100 
µg/ml Ampicillin.  The culture was then placed in a shaker at 37 ºC and grown overnight.  The 
bacterial culture was then pelleted using a centrifuge (6000 xg/ 15 minutes at 4 ºC), and the 
plasmid DNA was purified using Miniprep kit according to the manufacturer’s instructions 
(Qiagen).  Inserts were verified by DNA sequencing.  Positive clones were used to inoculate a 
larger volume of LB/Ampicillin (100 µg/ml), and large scale DNA plasmid preps were obtained 
using Qiagen Midiprep kit.   
For lentiviral transduction, three plasmids (transfer vector with expression construct, the 
packaging plasmid pCMV, and the VSV-G envelope protein expressing plasmid) were mixed in 
a ratio of 3:2:1 and transduced into 293T packaging cells using the Turbofect reagent 
(Fermentas) according to the manufacturer's protocol.  After 48 hours, supernatants containing 
the recombinant virus were collected every 24 hours and were centrifuged at 1500 rpm for 5-10 
minutes to remove dead cells. The virus-containing medium was used along with 3 µg/ml 
polybrene to infect BTBC cell lines by incubating the cells with the virus supernatant at 37ºC for 
a minimum of 6-8 hours.  Cells were treated with 4 µg/ml puromycin 48-72 hours post-infection 
to select for cells with genomic incorporation of the expression vector.  Lentivirus expressing a 
short hairpin targeting luciferase was used as a control in this experiment.  Anti-SHP2 
immunoblotting was used to confirm the level of SHP2 inhibition. 
 
2.5 Cell proliferation assay 
The 5-ethynyl-2'-deoxyuridine (EdU) proliferation assay was performed as described [52] 
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with slight modifications.  In brief, cells were seeded at 3x105 per well in six-well plates, then 
synchronized by adding DMEM medium containing 2% serum for 8 hours. 10 µM EdU was 
added to an approximately 40-50% confluent cells in each well for 24 hours.  Non-treated cells 
served as controls. To detect the amount of EdU incorporated into the DNA, the Click-iT EdU 
Alexa Flour 647 Cell Proliferation Assay Kit (Molecular Probes, Invitrogen, OR, USA) was used 
according to the manufacturer’s instructions.  Briefly, 0.5 x106   cells were harvested by 
trypsinization, washed twice with PBS containing 1% bovine serum albumin (BSA), then fixed 
in 100 µl Click-iT fixative for 15 minutes at room temperature in the dark.  For permeabilization, 
cells were washed twice in a saponin-based reagent. The Click-iT EdU reaction cocktail was 
prepared according to the manufacturer’s instructions and 500 µl per 0.5 x 106 cells was added to 
the cell pellet.  After 30 minutes of incubation at room temperature in the dark, cells were 
washed and analyzed using flow cytometry. 
 
2.6 Monolayer -wound healing assay  
To evaluate the impact of SHP2 inhibition on BTBC cells wound healing in vitro, a 
standardized scratch assay was used.  In detail, cells were grown to confluence in 6 cm dishes.  
Then the media was aspirated to remove floating dead cells, and replaced with fresh media.  A 
guiding arrow was also drawn on the bottom of the plate to orient pictures.  Two different 
scratches were made using a P200 pipette tip, and the fields were visualized and photographed 
using an Olympus IX71 microscope equipped with an Olympus DP30BW digital camera.  
Photos of the scratches were taken at 0, 8, and 12 hours. 
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2.7 Cell invasion assay 
To evaluate the impact of SHP2 inhibition on the invasive properties of BTBC cells, the dye 
quenched collagen IV (DQ collagen IV) served as a substrate in this assay.  Multiple fluoresceins 
are bound to collagen IV (Molecular Probes) but are quenched in the intact state due to the 
proximity of each fluoresceine residues to one another.  Collagen degradation by proteolysis 
generates a fluorescent signal that can be used as a read out for invasion.  In detail, Matrigel was 
mixed with 25 µg/ml DQ collagen IV.  Then the mixture was used to coat 4-well chamber slides 
(BD Falcon) which were left at 37ºC for 15 minutes to solidify.  25,000 cells were resuspended 
in 2% Matrigel mixed with DQ collagen IV and were seeded in the chambers.  Cells were 
observed over a period of 48 hours for the development of fluorescence using an Olympus IX71 
microscope equipped with an Olympus DP30BW digital camera. 
 
2.8  Mammosphere assay 
To assess the impact of SHP2 inhibition on the tumor initiating cells (TICs), the 
mammosphere assay was performed as described previously [53] with slight modifications.  
Briefly, cells were seeded at 1x104 cells per well in a six-well Ultra Low Attachment Plate 
(Corning, NY) and grown for 7 -10 days in serum free medium supplemented with B27 and 20 
ng/ml EGF.  Cells were fed once every 3 days with 1 ml serum free medium supplemented with 
growth factors.  The impact of SHP2 inhibition on mammosphere formation was determined by 
counting the acolonies 50 µm or more in diameter.  For serial passaging, mammospheres were 
harvested by gentle centrifugation at 800 rpm for 5 minutes, dissociated to single cells with 
trypsin treatment, and 1x104 cells were re-plated in a six-well plate and were cultured for 
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additional 10 days.  Resulting mammospheres were counted as above.   
 
2.9 Anchorage-independent growth assays 
Soft agar colony assays were performed as previously described [48].  Briefly, 6 cm cell 
culture plates were coated with 0.6% agar in growth medium.  1x105 cells were suspended in 
growth medium mixed with melted agar to a final concentration of 0.4%, then poured onto the 
agar bed.  A minimum of 10 fields per plate were counted, and the size cutoff was >50 µm in 
diameter.  Colony size was measured under a microscope, and phase contrast pictures were taken 
using an Olympus IX71 microscope equipped with an Olympus DP30BW digital camera.  
 
2.10 Ras activation assay 
Ras activation was determined by affinity precipitation with the Ras binding domain of Raf-1 
fused to glutathione-S-transferase (GST-RBD) as described previously [34].  Briefly, 
transformed bacteria with the pGEX-GST-RBD plasmid were inoculated in a culture of 50 ml 
Luria broth (LB) containing 100 µg/ml Ampicillin, then placed in a shaker at 37 ºC and grown 
overnight.  The culture was then transferred to 500 ml LB and the growth was continued for 90 
minutes (reaching an OD 600 nm of 0.8).  200 µM of Isopropyl b-D-thiogalactopyranoside 
(IPTG) was added and incubated for 2 hours to induce the fusion protein expression. The 
bacterial culture was then pelleted by  centrifugation (5000 rpm/10 minutes at 4 ºC) , then re-
suspended in 15–20 ml bacterial lysis buffer (20 mM Tris–HCl, pH 8.0, 150 mM NaCl, 1% 
Triton X-100, 10% glycerol, 1% NP-40, 2 mM EDTA, 1 mM PMSF, 1 µg/ml aprotinin, 1 µg/ml 
leupeptin).   Lysis was achieved by sonication by pulsing 3 times for 30 seconds for each sample, 
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until samples become clear (Amplitude knob setting at 37%), and the lysate was cleared by 
centrifugation (10000rpm/10 minutes at 4 ºC). The resulting GST-RBD fusion protein was 
purified on glutathione sepharose beads (20 µl packed volume per sample, GE Healthcare) by 
tumbling for 1 hour at 4 ºC, followed by washing 3 times with bacterial lysis buffer and 2 times 
with cell lysis buffer.  Breast cancer cells were serum-starved overnight, then stimulated with 20 
ng/ml of EGF in a time course manner for varying time points (10, 60, 120, 240 minutes).  Cells 
were lysed by washing twice with cold 1X phosphate buffered saline (PBS) followed by 
incubation on ice for 20 minutes with 500 µl of cell lysis buffer (20 mM Tris-HCl, pH 7.4, 150 
mM NaCl, 50 mM NaF, 1 mM EDTA, 10% glycerol, 1% Triton X-100, 1 mM sodium 
orthovanadate, 1 mM PMSF, 1 µg/ml aprotinin, 1 µg/ml leupeptin).  Equal amounts were 
tumbled with GST-RBD bound to the glutathione sepharose beads for 1 hour at 4 ºC.  Beads 
were washed three times with cold cell lysis buffer before mixing with 2X Laemmli sample 
loading buffer ( 0.125 M Tris-PH 6.8, 0.2M Dithiothrietol, 4 % SDS, 20 % glycerol, 0.02 % 
Bromophenol blue), and boiling for 10 minute at 100 ºC.  Samples were resolved on 12% SDS–
PAGE for immunoblot analysis. Then the separated proteins were transferred onto nitrocellulose 
membrane, blocked with 3% BSA in TBST, and the amount of Ras- pull down was assessed 
using anti-Ras monoclonal antibody. 
 
2.11  Gelatin zymography assay 
  MDA-MB-231 cells were grown in 6 cm dishes until 85-90% confluency, then serum-
starved for 24 hours before stimulation with 50 ng/ ml EGF.  Conditioned media was collected 
and concentrated using Amicon Ultra-4 centrifugal filter (10 kDa) according to the 
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manufacturer’s instructions. The amount of concentrated media was normalized to the amount of 
protein in the total cell lysate.  The concentrated media was mixed with a non-reducing SDS 
sample buffer without boiling and then loaded on a zymogram 10% gelatin gel (Novex 
EC6175BOX, Invitrogen).  After electrophoresis, the gel was washed twice with 2.5% Triton X-
100 using gentle agitation for 15 minutes.  The gel was then washed in developing buffer (50 
mM Tris base, 40 mM HCl, and 200 mM NaCl, 5 mM CaCl2, 0.02% (w/v) Brij 35) once for 30 
min before overnight incubation at 37ºC with gentle agitation.  Next, the gel was stained with 
0.5% Coomassie Blue R250 in a mixture of 50% methanol, 10% acetic acid, and 40% water for 
one hour at room temperature before destaining in the same mixture without the dye.  Serum-free 
medium (SF) and regular medium (RM) were used as a negative and a positive control, 
respectively.  Gelatinolytic activity was detected as a clear band against a blue background.  The 
degree of digestion was measured using a laser scanning densitometer. 
 
2.12 Tumor xenograft growth 
Experiments involving animals were approved by the Animal Care and Use Committee of 
the West Virginia University.  Mice used for this study were female nonobese diabetic/severe 
combined immune deficiency (NOD/SCID) mice aged 8-10 weeks obtained from the Jackson 
laboratory.  Breast cancer cells were suspended in 100 µl of a 1:1 mixture of growth media and 
matrigel (BD Biosciences) and were injected in the right fourth mammary fat pad.  Mice injected 
with MDA-MB-468 received 1.5x106 cells (6 mice); while the mice injected with MDA-MB-231 
received 2.5x106 cells (7 mice).   Tumor sizes were measured with a caliper twice weekly, and 
tumor volume was calculated using the formula (0.52 x length x width2) to estimate a spheroid 
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volume [41].  Tumors and potential metastatic sites including lung, liver and brain were 
harvested after euthanization by cervical dislocation for further analysis.  For histological 
purposes, frozen tumor sections were prepared, and then 7-µm thick sections were cut with a 
cryomicrotome, and stained with hematoxylin and eosin. 
 
2.13  Statistical analysis 
All statistical analyses were performed using GraphPad Instat3 software.  For comparisons of 
two groups of data, the Student’s t-test was used with 95% confidence intervals.  Results were 
considered statistically significant at an error probability level of p<0.05.  
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3. RESULTS 
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3.1 shRNA-mediated silencing of SHP2 expression 
The MDA-MB-231 and the MDA-MB-468 breast cancer cell lines were used as models to 
study the significance of SHP2 in BTBC. The MDA-MB-231 and the MDA-MB-468 breast 
cancer cell lines are basal-like and triple-negative as determined by expression of basal 
cytokeratins (CK5/6, 14 and 17), absence of HER2 overexpression (HER2-negative) and lack of 
nuclear accumulation of the estrogen and the progesterone receptors (ER/PR-negative) [54-56]. 
Furthermore, the MDA-MB468 cell line has an amplified EGFR gene [57, 58], and 
overexpresses the EGFR protein (3+ on IHC scale).  The MDA-MB-231 cell line has no such 
genetic change, but still expresses an elevated amount of the EGFR protein (2+ on IHC scale) 
[59].  
To investigate the impact of SHP2 inhibition on the tumorigenesis of BTBC cells, SHP2 
expression was constitutively ablated by two independent shRNAs designated as shRNA-I and 
shRNA-II. Western blot analysis of total cell lysates showed that the expression of SHP2 protein 
level was effectively reduced in shSHP2-I and shSHP2-II expressing cells relative to the control 
in both cell lines (Fig.1A and C).  Band density measurements confirmed that the SHP2 protein 
level was efficiently silenced by both shRNAs (~95% by shSHP2-I and ~80-90% by shSHP2-II) 
in both cell lines (Fig.1B and D). 
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Figure 2: Western blot analysis of total cell lyastes prepared from the control and shRNA cells 
of the MDA-MB-468 (A) and the MDA-MB-231 (C). Bar graphs showing band density 
measurements of SHP2 expression in the control and shRNA cells derived from the MDA-MB-
468 (B) and the MDA-MB-231 (D). The bar graphs show the normalized level of SHP2 
expression (normalized with β-actin levels).  
 
 
 
 
 
 
 
31 
 
3.2 SHP2 promotes BTBC cell proliferation 
In contrast to many other phosphatases, SHP2 promotes cellular processes such as cell 
proliferation and motility rather than inhibiting them. As a first step to study the role of SHP2 in 
BTBC, the impact of its inhibition on cell proliferation was investigated by the EdU (5-ethynyl-
2´-deoxyuridine) incorporation assay.  EdU is a nucleoside analog of thymidine that gets 
incorporated into replicating DNA during S-phase.  The EdU incorporation assay involves 
labeling of cells for 24 hours and detection by flow cytometery after counter staining with EdU-
specific azide that is tagged with Alexa Flour 647.  As shown in (Fig.3A), a larger percentage of 
the control cells incorporated EdU, compared to the shRNA cells.  The bar graph further 
confirms that SHP2 depletion in MDA-MB-231 cells resulted in approximately 37% loss of cell 
proliferation relative to the control (Fig.3B). 
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Figure 3: SHP2 knockdown suppresses cell proliferation in MDA-MB-231.  (A) Representative 
histograms showing the number of cells stained with EdU- Alexa Flour 647.  (B) Bar graph 
showing SHP2 depletion resulted in 37% loss of cell proliferation (P< 0.0021).  Data is 
represented as mean ± SEM of triplicates.  
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3.3 SHP2 depletion suppresses anchorage-independent growth in BTBC cells 
Anchorage independent growth is one of the in vitro properties of a cancer cell that is utilized 
as a marker for cellular transformation.  Therefore, it is routinely used to determine the impact of 
gene manipulation or drug treatment on cancer cell transformation.  Seeding cells in soft agar 
suspends cells from attaching to the bottom of culture plates, providing anchorage-independent 
growth conditions.  To evaluate a potential role for SHP2 in this process, approximately 1 x 105 
cells from each cell line were seeded in 4% soft agar.  After 3-4 weeks of incubation, the impact 
of SHP2 depletion on colony growth was determined by counting the number and/or measuring 
the size of the colonies that were larger than 50 um in diameter under a microscope.  
Representative micrographs showed that the MDA-MB-231 control cells formed more colonies 
in 3 weeks than the shRNA cells (Fig.4A).  Similarly, the control cells derived from MDA-MB-
468 cells formed more colonies than the shRNA cells (Fig.4C).  Determining colony number 
further confirmed that inhibition of SHP2 suppressed colony formation by approximately 80% in 
the MDA-MB-231 cells (Fig.4B) and by approximately 40% in the MDA-MB-468 cells 
(Fig.4D).  Although SHP2 inhibition had a relatively modest impact on colony number in the 
MDA-MB-468 cells, it had a significant impact on colony size; inhibition of SHP2 reduced 
colony size by approximately 62% (Fig.4E). Collectively, these observations provide evidence 
showing that SHP2 is required for the anchorage independent growth of BTBC cells.   
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Figure 4: SHP2 suppresses anchorage-independent growth in the MDA-MB-231 and the 
MDA-MB-468 cells.  Representative micrographs of MDA-MB-231 (A) and MDA-MB-468 (C) 
showing that the control cells formed more and larger colonies than the shRNA cells.  Bar graphs 
showing colony number per field for the MDA-MB-231 (B) and for the MDA-MB-468 (D) cells.  
The bar graph in (E) depicts colony size for the MDA-MB-468 cells.  Data is represented as 
mean ± SEM from three independent experiments.  
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3.4 SHP2 is required for the migration of BTBC cells 
Previous work has demonstrated a function for SHP2 in regulating cell motility in other cell 
lines [60, 61].  To further investigate the impact of SHP2 depletion in BTBC cell migration, 
wound-healing assays was performed on confluent cell monolayers.  In agreement with previous 
observations, control cells derived from MDA-MB-231 cells filled the scratch wound within 24 
hours, while the shRNA cells were unable to do so within the same period of time (Fig.5A).  
Similar results were obtained when these experiments were repeated in the MDA-MB-468 
derived cells (Fig.5B).  These results indicate an important role for SHP2 in BTBC cells 
migration. 
 
Figure 5: SHP2 inhibition suppresses migration in BTBC cells: Representative micrographs 
showing impact of SHP2 inhibition on monolayer wound healing in the MDA-MB-231 (A) and 
the MDA-MB 468 (B) cells taken at the indicated time points.  
 
 
37 
 
3.5 The invasive property of BTBC cells is SHP2 dependent  
To investigate the contribution of SHP2 depletion on BTBC cell invasion, the 3D DQ-
collagen in Matrigel assay was used.  When grown in 3D matrix, cells migrate and invade the 
surrounding ECM degrading DQ collagen IV.  Degradation is measured by fluorescence 
microscopy as an accumulation of fluorescence products.   Phase contrast microscopy images of 
MDA-MB-231 control cells showed that these cells grew as a cluster in the 3D matrix, with 
some cells extending a finger-like protrusion that were not observed in the shRNA cells (Fig.6A, 
lower panel).  Furthermore, green fluorescent spots around the colonies were present in control 
cells and much lower fluorescence signals were observed in the shRNA cells (Fig.6A, upper 
panel).  Similar results were observed using MDA-MB-468 cells (Fig.6B).  Taken together, these 
results demonstrate that SHP2 is fundamental for the invasion process of BTBC cells, either 
through regulation of cell migration or proteolytic mediated ECM degradation.  
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Figure 6: SHP2 inhibition suppresses invasion in BTBC cells: Representative phase images 
(lower panel) and fluorescence images (upper panel) showing impact of SHP2 inhibition on DQ 
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collagen IV degradation in the MDA-MB-231 (A) and the MDA-MB 468 (B) cells. The 
micrographs were taken at the 24 hours time point.   
3.6 Loss of SHP2 decreases the level of matrix metalloproteinase 9 (MMP9) in conditioned 
media 
MMP9 and MMP2 are two members of the matrix metalloproteinase family that are 
expressed in human cancers and are thought to play critical role in tumor invasion and metastasis 
[5, 62].  Both MMPs have been implicated in the degradation of collagen IV, a major component 
of the basement membrane [62].  Hence, both are believed to contribute to the invasiveness of 
breast cancer cells.  Previous reports presented evidence showing that SHP2 is required for the 
production and proteolytic activation of MMP2 and MMP9 in fibroblasts stimulated with 
Concanavalin A [63, 64].  Moreover, SHP2 has also been shown to play a role in the increased 
level of MMP9 in the conditioned media of the MCF7 breast cancer cell line stimulated with IL-
1B [65]. 
Here, gelatin zymography was used to investigate whether SHP2 is involved in the regulation 
of MMP9 and MMP2 levels in the conditioned media of the MDA-MB-231 cells.  Cells serum-
starved overnight were stimulated with EGF (20 ng/ml) for 6 hours or left un-stimulated. 
Conditioned media was collected and assayed by gelatin zymography.  Zymograms showed a 
reduction in the amount of degradation due to reduction at the level of MMP9 following SHP2 
inhibition (Fig.7A and C).  Band density measurements confirmed that SHP2 depletion resulted 
in an approximately 40% reduction in MMP9 activity compared to the control (Fig.7B).  
Furthermore, EGF treatment resulted in an increase in MMP9 activity in control cells, whereas 
SHP2 depletion rendered cells non-responsive to EGF treatment (Fig.7B).  Immunoblotting of 
the same conditioned media with anti-MMP9 antibody further confirmed a drastic reduction in 
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MMP-9 levels as a result of SHP2 depletion (Fig.7C).  Reprobing with an anti-β-actin antibody 
showed that contamination of the conditioned media with cell lysate was minimal (Fig.7C).  To 
rule out the possibility that the observed difference in MMP9 level in the conditioned media was 
not due to variation in cell density, cell lysates prepared from same cultures were analyzed for 
total protein content and SHP2 expression. As shown in (Fig.7D), total protein levels were 
comparable in all lanes, and SHP2 expression was effectively silenced in the shRNA cells.  
These results indicate that SHP2 positively regulates MMP9 levels in conditioned media, but do 
not distinguish whether or not such role is a result of an effect on the secretion or expression of 
MMP9. 
 
Figure 7: SHP2 depletion decreased MMP9 level in condition media of MDA-MB-231:  (A) 
Gelatin zymography showing a reduction in MMP9-mediated degradation in the shRNA cells 
compared to controls.  (B) Band density measurement of zymography.  (C) Immunblotting 
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analysis of conditioned media for MMP9 and β-actin.  (D) Immunobotting analysis of total cell 
lysates for β-actin and SHP2.  
3.7 Depletion of SHP2 suppresses the tumorigenic potential of BTBC cells 
Very recent reports have demonstrated a functional role for SHP2 in tumor maintenance and 
progression using different cell lines, including breast cancer cell lines [41, 49].  Having 
observed that SHP2 plays a significant role in the transformation process of BTBC cells in vitro, 
we asked whether SHP2 is involved in the tumorigenesis process in vivo.  To test this, we 
investigated the effect of SHP2 depletion on the tumor growth of both MDA-MB-231 and MDA-
MB-468 cells orthotopically transplanted into the mammary fat pads of female NOD/SCID mice 
approximately 8 weeks old at the time of injection. The tumor volume measurements showed 
that SHP2 depletion in the MDA-MB-468 cells resulted in a significant decrease in the xenograft 
tumor growth rate.  While the control tumors reached ~3500 mm3 in 7 weeks, the shSHP2-II 
tumors were ~700 mm3 by the same period of time (Fig.8A).  In other words, the control tumors 
grew ~5 times larger than the shSHP2 tumors. Furthermore, the tumor weights collected at the 
time of termination from mice injected with MDA-MB-468 cells showed that SHP2 depletion 
resulted in a drastic decrease in the mean tumor weight (Fig.8C).  Although the growth rate of 
tumors formed by the MDA-MB-231 cells was very slow, reaching ~60 mm3 for the controls in 
8 weeks, the overall trend of SHP2 inhibition on tumor growth was similar to that observed in 
the MDA-MB468 cells (Fig.8B).  These data provide evidence that SHP2 promotes the growth 
of BTBC tumors. 
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Figure 8: SHP2 promotes tumorigenesis of BTBC cells: Tumor growth rate was determined 
by measuring tumor volume as described in the materials and methods. Note that the control 
cells derived from the MDA-MB-468 (A) are highly tumorigenic and inhibition of SHP2 
suppressed this potential significantly.  On the other hand, cells derived from the MDA-MB-231 
(B) were less tumorigenic, but the impact of SHP2 inhibition was similar.  Data shown is mean ± 
SEM of tumor volume.  MDA-MB-468: Control n = 3, shSHP2-II n = 3; MDA-MB-231: 
Control n = 3 and shSHP2-II n = 4.  (C) Bar graph showing mean tumor weight (g) ± SEM for 
the MDA-MB-468 tumors.   
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3.8 Loss of SHP2 suppresses lung metastasis. 
To determine whether or not SHP2 is required for the metastatic potential of the BTBC 
tumors, lungs harvested from mice bearing the control- and shSHP2-II-expressing tumors were 
analyzed by histological evaluation following hematoxylin and eosin staining.  Microscopic 
examination showed no metastasis in the lungs of both control and shSHP2-II mice that bore 
MDA-MB-468 tumors (data not shown), suggesting that these cell lines are highly tumorigenic, 
but not metastatic.  On the other hand, the lungs from all of the control mice that had MDA-MB-
231-derived mammary tumors had massive metastasis (Fig.9).  Surprisingly, the lungs of 
shSHP2-II mice had no observable metastatic cells suggesting that SHP2 is required not only for 
tumor growth, but also for metastasis of the MDA-MB-231 cells. 
  
Figure 9: SHP2 inhibition abolishes the metastatic potential of the MDA-MB-231 cells. 
Representative H&E stained sections of lungs from mice bearing MDA-MB-231-Control or 231-
shSHP2-II tumors are shown. Metastases were found in 3 out of 3 animals in the control group 
and none were found in animals bearing tumors expressing shSHP2-II. 
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3.9 SHP2 depletion decreases self-renewal of tumor initiating cells (TICs) 
Tumors, similar to normal tissues, are believed to be composed of cells with different 
differentiation states and variable capacity for self-renewal [66] .  It has been shown that 
minority cell populations within a tumor have the capacity to self-renew, and as such, they are 
responsible for perpetual growth of a tumor [67].  Serial passaging experiments have 
demonstrated that only self renewing tumor cells have the capacity to initiate new tumors when 
transplanted into immune deficient mice [66].  These minority populations are referred to as 
tumor initiating cells (TICs) or cancer stem cells, multipotent tumor cells with the capacity to 
self-renew and to recapitulate the tumors they are derived from upon transplantation into 
immune-deficient mice [66].  TICs can be characterized by specific cell surface antigens such as 
CD44+/CD24-, accompanied by ALDH1 expression, and by the mammosphere assay, an in vitro 
assay that can also be used to enrich for the TICs that are able to grow as spheres in anchorage-
independent, growth factor enriched, and serum-free conditions [68]. 
The observation from the soft agar assay where it took at least 3-4 weeks to see any 
difference in colony numbers between the SHP2-depleted cells compared to the control cells, as 
well as the drastic difference in xenograft tumor volume, led us to investigate the effect of SHP2 
depletion in the self-renewal capacity of TICs using the mammosphere assay.  We measured the 
mammosphere formation efficiency of BTBC cell lines in the presence or upon SHP2 depletion.  
To assess whether SHP2 influences the self-renewal of TICs, we dissociated the primary 
mammospheres into single cells and reseeded them.  As shown in (Fig.10A), SHP2 depletion 
resulted in a significant decrease in the ability of both MDA-MB-231 and MDA-MB-468 cells to 
form mammospheres. Interestingly, the ratio of secondary to primary mammospheres was lower 
in shSHP2 cells than in the control cells, showing that SHP2 depletion decreases the self renewal 
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capacity of TICs (Fig.10B).  Thus, SHP2 is required for the self-renewal capacity of TICs in 
BTBC cells. 
 
Figure 10: SHP2 knockdown decreases TICs self-renewal.  Mean mammospheres formation 
(A) and self-renewal capacities (B) of MDA-MB-231 and MDA-MB-468 cells in the presence or 
upon SHP2 depletion.  Self-renewal was reduced in the absence of SHP2.  Results were 
represented as means ±SEM of the triplicates. 
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3.10 SHP2 in BTBC cells signaling. 
3.10.1 SHP2 is important for EGF-induced Ras activation 
SHP2 has emerged as a major regulator of the Ras/MAPK pathway downstream of receptor 
tyrosine kinases (RTK), especially pathways activated by EGFR [34].  To define the signaling 
pathways in BTBC cells that rely on SHP2 action, the state of Ras activation was determined in 
the MDA-MB-468 control- and shSHP2-expressing cells using the Ras binding domain of Raf-1 
fused to GST (GST-RBD) as a reagent [22].  Because SHP2 is known to be required for 
increasing the intensity and duration of signaling induced by ligand-activated RTKs, these 
experiments were conducted in time-course manner by stimulating cells with EGF for varying 
time points.  As shown in (Fig.11A), EGF-induced Ras activation was sustained for about 4 
hours in control cells, whereas it was short-lived in the shSHP2 cells.  Band density 
measurements from two different experiments further confirm this observation (Fig.11B).  
Immunoblotting of total cell lysates showed that the amount of total Ras level was comparable in 
all lanes, and the state of SHP2 depletion in the shSHP2 cells was efficient (Fig.11A).  These 
results show that SHP2 is required for sustained Ras activation in MDA-MB-468 cells.   
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Figure 11: SHP2 is required for sustained Ras activation in MDA-MB-468: (A) MDA-MB-
468 cells were serum starved and stimulated with EGF (20 ng/ml) as indicated.  Cell lysates were 
analyzed by immunoblotting with antibodies for Ras, GST, ERK2, and SHP2.   (B) The bar 
graph showing SHP2 knockdown resulted in a short-lived Ras activation. 
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3.10.2 SHP2 modulates β-catenin and downstream signaling 
Recently, SHP2 has been implicated in modulating Wnt signaling.  One of the suggested 
SHP2 substrates that mediates the effect in Wnt signaling is parafibromin/Cdc73 [39].  Other 
reports have also shown SHP2 modulating c-Myc and p27 protein levels in prostate, lung and 
breast cancer cell lines [41, 49].  
The possibility of SHP2 modulates the Wnt-β-catenin signaling pathway in BTBC cells was 
explored.  First, the level of β-catenin in the control and shSHP2 cells derived from the MDA-
MB-468 cells was examined by immunoblotting of total cell lysates.  As shown in (Fig.12A), 
depletion of SHP2 resulted in a decreased level of β-catenin.  Further, reprobing for the cell cycle 
regulator protein p27, a known transcriptional target of β-catenin, showed an increase in shSHP2 
cells, which may explain the observed suppression of cell proliferation (see Fig. 12A) upon 
SHP2 depletion.  Immunoblotting with anti-β-actin and anti-SHP2 antibodies showed 
comparable loading and efficient silencing, respectively.  The band density measurements further 
confirmed impact of SHP2 depletion on β-catenin, and p27 (Fig.12B).   
Furthermore, immunoblotting of tumor lysates collected from MDA-MB-468 xenograft cells 
confirmed persistent reduction in β-catenin levels in SHP2 depleted tumors.  Altogether, these 
results suggest that SHP2 may promote the tumorigenic potential of BTBC cells through 
modulation of β-catenin levels. 
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Figure 12: SHP2 modulates β-catenin, and p-27 protein levels in the MDA-MB-468 cells. 
(A) Immunoblotting analysis of control and shSHP2 lysates for the indicated proteins.  (B) The 
bar graph showing SHP2 depletion leading to reduction in β-catenin and an increase in p27 
levels.  (C) Immunoblotting analysis of tumor lysates derived from 3 controls and 3 shSHP2 
mice for the indicated proteins. 
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4. DISCUSSION 
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4.1 SHP2 as a potential target in BTBC 
Breast cancer continues to be a major health problem effecting women worldwide.  Of 
particular concern is BTBC that is associated with poor prognosis and does not respond to 
standard targeted therapies.  Still, no effective targeted therapy has been identified to date for this 
subtype; and there is a great need for identifying signaling proteins that play critical roles in the 
development of BTBC.  Overexpression of EGFR often occurs in BTBC cell lines and tumors 
[15].  In addition, phosphorylation of EGFR has been found to be higher in BTBC than the 
luminal subtype, suggesting more active pathway [69].  Furthermore, the RAS/MAPK and the 
Wnt/β-catenin pathways are activated and highly involved in tumor progression of BTBC [70, 
71].  SHP2 is well-known to positively modulate these pathways, especially the one elicited by 
EGFR.  It is unknown, however, to what extent SHP2 is involved in the development and 
signaling of BTBC.  Therefore, it was of interest to investigate whether SHP2 plays a role in the 
tumorigenesis of BTBC.  To study this possibility, we generated two different anti-SHP2 
shRNAs that have been previously reported to successfully silence SHP2 [72].   Then, the anti-
SHP2 shRNAs were used interchangeably to assess the effects of SHP2 depletion on BTBC cell 
proliferation, transformation, migration, invasion and xenograft growth.  Finally, we dissected 
the roles of SHP2 in EGF-induced Ras activation and in Wnt/β-catenin signaling.   
 
4.2 SHP2 knockdown results in decreased cell proliferation 
As a first step to study SHP2 role in the tumorigenesis of BTBC cells, we sought to 
investigate the effect of SHP2 knockdown on cell proliferation.  Using the EdU assay we found 
that SHP2 depletion resulted in a 37% decrease in cell proliferation of MDA-MB-231 cells 
(Fig.3B).  These results were consistent with previous reports showing that SHP2 is important 
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for cell proliferation of normal and cancer cell lines [24, 41, 73, 74].  For example, one of the 
first lines of evidence linking SHP2 to cell proliferation came from the observation that insulin-
induced cell proliferation of the 3T3 cells was suppressed by the ectopic expression of mutant 
SHP2CS form [24, 33].  Similar results were obtained in mouse fibroblast expressing mutant 
SHP2 upon treatment with EGF and PDGF [74].  Furthermore, SHP2 has been shown to be a 
critical mediator of cell growth and transformation of 3T3 cells expressing the constitutively 
active form of fibroblast growth factor receptor-3 (FGFR-3) [75].  While others have shown that 
SHP2 promote cell proliferation of prostate and lung cancer cell lines [41]. Taken together, these 
findings suggest that SHP2 promotes tumorigenesis at least partly by promoting cell 
proliferation. 
 
4.3 Inhibition of SHP2 suppresses cell transformation 
One important hallmark of cancer cells is their ability to grow in an anchorage-independent 
manner.  Therefore, a soft agar assay is routinely used to determine the impact of gene 
manipulation or drug treatment on cancer cell transformation.  Here, we demonstrated that SHP2 
inhibition suppressed BTBC cell transformation, as evidenced by the loss of anchorage-
independent growth (Fig.4 (A-D)).  These findings are consistent with the reports indicating that 
SHP2 is required for cell transformation induced by the constitutively active form of FGFR-3 
and v-Src [75, 76].  They are also in agreement with a previous report implicating a role for 
SHP2 in the transformation phenotype of various breast cancer cell lines [48].  Collectively, 
these observations confirm that SHP2 plays a significant role in the transformation process in 
vitro and suggests a role for the enzyme in tumorigenesis in vivo. 
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4.4 Depletion of SHP2 suppresses BTBC wound healing in vitro 
The wound healing assay is one of the earliest methods that have been developed to 
monitor cell behaviors, including cell migration and proliferation [77].  Using the wound healing 
assay, we found that depletion of SHP2 suppressed the ability of BTBC cells to fill wounded 
regions (Fig. 5(A and B)).  Our findings were consistent with a previous report implicating a role 
for SHP2 in the wound healing process of breast cancer cell lines [48].  Furthermore, a modified 
chamber assay demonstrated that fibroblast cells lacking a functional SHP2 have impaired 
migration and spreading associated with increased focal adhesions [60, 61].   Collectively, these 
observations confirm a role for SHP2 in the wound healing process in BTBC and suggest that 
SHP2 regulates cell migration and probably metastasis of BTBC cells.  
 
4.5 SHP2 knockdown results in decreased cell invasion 
Elucidating the signaling molecules that play role in invasion could provide a mechanistic 
understanding of the invasion process [78].  Here, using a 3D assay which more accurately 
reflects the tumor microenvironment, we demonstrated that SHP2 inhibition suppressed BTBC 
cell invasion, as evidenced by the loss of ability to degrade DQ-collagen embedded in Matrigel 
(Fig.5 (A and B)).  Interestingly, SHP2 has been shown to regulate the activity of the signaling 
molecules that are involved in invasion such as Fyn and p190RhoGap [78].  For example, SHP2 
recruitment and activation with subsequent Fyn activation is essential for the α6β4 integrin to 
optimally promote invasion in breast cancer cell lines [78].  Moreover, recent report has shown 
that SHP2 is fundamental to breast cancer invasion ex vivo and in vivo [49]. 
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In agreement with previous reports our observations confirm that SHP2 plays a significant 
role in the invasion process in vitro, and suggests that targeting SHP2 in BTBC may be useful for 
blocking this crucial cancer hallmark. 
 
4.6 SHP2 depletion decreases MMP9 levels in conditioned media 
The previous observation pointing at an important role for SHP2 in cancer cell invasion using 
the 3D assay, have led us to investigate whether SHP2 affects the production of matrix 
metalloproteinase.  For example, MMP9 and MMP2 have been implicated in the degradation of 
collagen IV a major component of the basement membrane [64].  Degradation of basement 
membrane is considered the first crucial step in tumor cell invasion, and cancer cells must be 
able to mobilize and produce matrix metalloproteinases to be able to breach this barrier [62].  
Increased expression of MMP2 and MMP9 has been observed in breast tumors in both stromal 
and cancer cells [79].  Moreover, it has been shown that stimulation of the cell with growth 
factors, cytokines, and lectins such as concanavalin A (ConA) further promotes the secretion of 
MMP9 [62-64, 79]. 
In this study we found that depletion of SHP2 in MDA-MB-231 resulted in a drastic decrease 
in MMP9 level in the conditioned media (Fig.7B).    The results demonstrated that the enzyme 
was in the latent form, as reflected by its molecular mass of 92 kDa, and not in the active form 
(82 kDa) (Fig.7A).  Furthermore, EGF induced the secretion of MMP9 in the control cells; 
however, depletion of SHP2 rendered the cell nonresponsive to EGF stimulation (Fig.7A).  
Whether the decreased level of MMP9 in the conditioned media was due to increased protein 
expression or secretion was not investigated. 
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Previous work in fibroblasts cells expressing mutant SHP2 has implicated the phosphatase in 
the production and secretion of MMP2 and MMP9 upon stimulation with Con A [63, 64].  
Furthermore, using MCF-7 cells SHP2 has been shown to regulate secretion of MMP9 upon 
stimulation with IL-1B [65].  Thus, SHP2 appears to regulate MMP9 activity in both normal and 
malignant cells.  Our results indicate the effect of SHP2 on MMP9 was specific, since MMP2 
was not affected by SHP2 depletion or EGF stimulation in these cells (data not shown).  This is 
consistent with the difference in the transcriptional regulation of MMP2 and MMP9, since 
different response elements are present in their promoter regions [79].  However, unlike the 
previous report in the normal fibroblasts, we did not see any difference in MMP2 level in the 
conditioned media upon SHP2 inhibition in MDA-MB-231 cells. 
In conclusion, our results suggest that SHP2 may modulate invasion of metastatic breast 
cancer cells in part by increasing the secretion/expression of MMP9. 
 
 4.7 SHP2 knockdown suppresses BTBC xenograft tumor growth and lung metastasis 
The findings that SHP2 depletion suppressed BTBC cell proliferation and transformation in 
vitro raised the possibility that SHP2 is also required for tumorigenesis in vivo.  Here, we 
provided evidence showing that SHP2 is indeed required for tumor maintenance and progression 
of BTBC in vivo (Fig.8A-C).  Furthermore, using metastatic cell lines such as MDA-MB-231, 
we demonstrated that SHP2 depletion abolished lung metastasis (Fig.9).  These results were 
consistent with recent reports implicating SHP2 in tumor growth in vivo using different cell types 
[41, 49].  Altogether, these findings reveal an important role for SHP2 in tumor growth of BTBC 
and establish an important role for SHP2 in tumorigenesis in vivo. 
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 4.8 Inhibition of SHP2 suppresses the self-renewal capacity of TICs 
Previous observations pointing at the role for SHP2 in the transformation and tumorigenesis 
of BTBC, have led us to investigate the effect of SHP2 depletion on the self-renewal capacity of 
the TICs.  The mammosphere assay was used to assess this possibility.  First, we demonstrated 
that SHP2 depletion resulted in a significant decrease in the mammosphere numbers (Fig.10A).  
Second, we showed that SHP2 depletion suppressed the self-renewal capacity of the TICs 
(Fig.10B).  Our findings were consistent with the previous report showing that SHP2 influence 
the self-renewal capacity of TICs in HER2- positive and triple negative breast cancer cell lines 
[49].  Collectively, these findings confirm that SHP2 promote the self-renewal capacity of TICs 
in breast cancer cell lines. 
 
 4.9 SHP2 signaling in BTBC cells 
4.9.1 SHP2 regulates EGF-induced Ras activation in BTBC cells 
Genetic Ras mutation is infrequent in breast cancer; however, the Ras signaling pathway gets 
abnormally activated in tumors overexpressing growth factor receptors such as EGFR and  
HER2 [71].  Specifically, BTBC tumors tend to overexpress EGFR.  Since SHP2 is a major 
regulator of the Ras/MAPK pathway downstream of RTKs, we hypothesized that the regulation 
of tumorigenesis was mediated through the control of this particular pathway.  We found that 
SHP2 is required for sustained EGF-stimulated Ras activation in MDA-MB-468 (Fig.11A).  
Therefore, it is likely that SHP2 mediates part of its effect on tumorigenesis of BTBC through 
the regulation of EGF-induced Ras activation.   
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4.9.2 SHP2 regulate the Wnt/β-catenin signaling in BTBC cells 
The Wnt/β-catenin pathway is a major regulator of cellular processes including cell 
proliferation, migration, and differentiation.  This makes it one of the significant pathways that 
are implicated in embryonic development and tumorigenesis [80].  Upon Wnt activation β-
catenin is translocated from the membrane to the nucleus where it interacts with transcriptional 
activators to modulate the expression of target genes such as c-myc, CD1, or p27 genes 
associated with increased cell growth, invasion, and transformation [70, 81].   Several reports 
have shown that the Wnt/β-catenin signaling pathway is activated in basal type and triple 
negative breast cancer, and this activation is associated with poor outcome [70, 82]. 
Here, we found that one of the mechanisms through which SHP2 exerts its effects on 
tumorigenesis requires the Wnt/β-catenin pathway.  We demonstrated that SHP2 knockdown in 
MDA-MB-468 cells resulted in depletion of β-catenin protein levels, which resulted in an 
increase in p27 protein levels.  These findings uncover a previously unknown mechanism of β-
catenin regulation by SHP2 and identify a SHP2-dependent signaling role that enhances the 
maintenance and progression of BTBC xenografts.  Finally, to assess the generality of this 
mechanistic finding, we analyzed the effect of SHP2 depletion on β-catenin levels in two 
different cell lines, MDA-MB-231 and BT20 (data not shown).  Unfortunately, SHP2 inhibition 
did not affect β-catenin in these cell lines, suggesting that the mechanism we provided here could 
be cell specific for MDA-MB-468 cells. 
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4.10 Study limitations and future directions  
The protein tyrosine phosphatase SHP2 can act at multiple signaling sites simultaneously to 
regulate multiple cellular processes including cell growth, survival, motility, and apoptosis [29].  
We have demonstrated an effect for SHP2 in cell proliferation under cell culture; however we 
did not investigate the effects of SHP2 on other cellular processes in this study in vivo.  It would 
be of interest to investigate the role of SHP2 in BTBC cellular pathways in vivo.  For example, 
we can investigate apoptosis by staining the frozen xenograft tumor sections with caspase 3, a 
marker of induced apoptosis.   
Angiogenesis is one of the rate limiting steps in tumor progression in vivo.  Inadequate blood 
supply will impair the ability of the tumor to proliferate and metastasize to other sites.  
Therefore, it would be of interest to stain the frozen xenograft tumor sections with CD31, a 
marker for blood vessel enrichment in the tumor sections.  For a definitive assessment of the role 
of SHP2 in cell proliferation in vivo, it would be of interest to stain the frozen tumor sections 
with the proliferation marker Ki67.   
Although we could show that SHP2 knockdown in MDA-MB-468 resulted in depletion of β-
catenin, we did not investigate whether this was a result of SHP2 depletion and not an off-target 
effect of the shRNAs used to target SHP2.  The fact that we generated two different anti-SHP2 
shRNAs that gave the same results indicates specificity toward SHP2 and excludes any off-target 
effect.  However, it would be of interest to rescue SHP2 expression, and investigate whether it 
will also rescue β-catenin level.  Afterwards, we can investigate the mechanism into how SHP2 
depletion results in decreased β-catenin level in MDA-MB-468 cells. 
Stable knockdown of SHP2 resulted in an effective suppression of tumor growth in vivo and 
abolished lung metastasis.  However, effect on metastasis could actually result from SHP2 
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depletion affecting cell proliferation and decreasing tumor burden rather than a direct effect on 
metastasis.  Therefore, for a more accurate representation of the effects of SHP2 depletion on 
metastasis in vivo, it would be of interest to use an inducible system because SHP2 tumor burden 
would be in place at the time of SHP2 knockdown.   
We demonstrated an effect for SHP2 knockdown on MMP9 protein level in conditioned 
medium.  However, the results that we provided cannot distinguish whether the effect of SHP2 
depletion was a result of an effect on secretion or production of MMP9 in MDA-MB-231 cells.  
To answer this question, it would be of interest to investigate MMP9 mRNA and protein 
expression in whole cell lysate under condition of SHP2 knockdown. 
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5. SUMMARY AND CONCLUSION 
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Tyrosine phosphorylation is an important signaling event that regulates several cellular 
processes such as cell growth, survival, migration, differentiation and apoptosis [25]. Aberrant 
regulation of tyrosine phosphorylation is linked to the development of cancer and other human 
diseases [28]. Several experimental studies demonstrate that altered expression or mutations in 
protein tyrosine kinases (PTKs) are linked to the development of many forms of human cancer 
[42]. However, our knowledge on the role of protein tyrosine phosphatases (PTPs) in cancer 
pathogenesis lags behind our understanding of kinases.  Relatively, little is known about the role 
of some PTPs contributing to cancer pathogenesis and progression, especially regarding the 
connection of SHP2 with solid tumor progression.  In this study we investigated the role of the 
protein tyrosine phosphatase SHP2 in the tumorigenesis of BTBC in vivo.  BTBC represents the 
most challenging subtype of breast cancer to treat, and new therapeutic targets are urgently 
needed. 
Here, we demonstrated that SHP2 knockdown resulted in decreased cell proliferation, 
transformation, migration and invasion of BTBC cells.  More importantly, we showed that SHP2 
is required for BTBC xenograft tumor maintenance and progression, and its depletion abolished 
lung metastasis.  In exploring the molecular mechanism by which SHP2 mediates its effects, we 
demonstrated that SHP2 is required for sustained EGF-induced Ras activation in MDA-MB-468 
cells.  Furthermore, we discovered that SHP2 regulates the Wnt/β-catenin signaling pathway in 
MDA-MB-468 cells.  In addition, we demonstrated a role for SHP2 in the propagation and the 
self-renewal capacity of TICs.  In conclusion, these findings suggest SHP2 plays an essential role 
in BTBC development and reinforce the concept of developing a specific inhibitor targeting 
SHP2 in BTBC. 
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